Business Wire

ADVA

Share
ADVA demos Europe’s first 5G rail deployment

ADVA (FSE: ADV) today announced that it has successfully demonstrated Europe’s first 5G rail deployment in an operational environment. Using a combined optical and microwave transport solution, the demo succeeded in delivering multi-Gbit/s connectivity to fast-moving trains. Until now, supporting the handovers required for consistent broadband connectivity on trains traveling at speed was a major challenge. Built on ADVA’s G.metro passive optical technology and FSP 150 edge aggregation solution , the joint trial featured an integrated architecture for all train communication applications. Millimeter wave (mmWave) access points (APs) were used to maintain track-to-train connectivity as well as programmable mobility functions for seamless onboard services. Part of the EU’s Horizon 2020 5G-PICTURE project, the demo was conducted by ADVA, Blu Wireless Technology, CNIT, COMSA Industrial and the local railway operator and infrastructure manager, Ferrocarrils de la Generalitat de Catalunya (FGC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200121005201/en/

“With this demo, we’ve presented the blueprints for the future of rail telecommunication networks. We’ve shown how a combined optical and microwave 5G architecture can carry both critical and non-critical communications, dramatically simplifying deployments and delivering significant cost reduction,” said Jim Zou, senior engineer, advanced technology, ADVA. “Unlike traditional railway telecommunication networks that rely on separate infrastructures, what we’ve proposed with this demo is a unified, automated network able to support every application and prevent service interruptions. It delivers high-bandwidth internet access to passengers on the move, while also providing train operators with driver-to-control connectivity, access to surveillance cameras and mission-critical onboard applications. Now a single 5G network can provide all telco services for train companies, freight operators and passengers.”

Deployed across three stations of the FGC network in Barcelona, the 5G-PICTURE railway testbed interconnected a variety of end-user devices and compute resources using the most advanced optical and wireless network technologies. For the first time in Europe in a live operational scenario, the demo proved that a single integrated infrastructure can deliver safe, secure and reliable connectivity for all three categories of train line services: critical, performance and business. Along the track, it leveraged mmWave links that intelligently steered beams to the train’s rooftop antennae for optimal backhaul and access connectivity. These were connected to passive WDM add/drop nodes built with ADVA’s low-latency G.metro system and each mmWave AP was capable of dedicated 10Gbit/s connectivity. All the traffic from the trackside was further aggregated to the railway operator’s core network based on ADVA’s 100Gbit/s Ethernet aggregation technology.

“At FGC, we understand the value of leveraging emerging technology to achieve maximum efficiency and provide our passengers with the best available services. That’s why we’re so excited by the possibilities that this demo presents. It showed how we can harness an intelligent, open and scalable 5G network for everything from surveillance to passenger communications to mission-critical operational data transport,” commented Carles Terés Casals, director, R&D, FGC. “Train passengers are heavy users of mobile data. Whether it’s video streaming, replying to emails and social media or planning the next stage of their journey, they expect always-on access to advanced services. Providing ultra-reliable high-speed mobility on a virtual infrastructure shared with all other applications offers a way to meet that demand while removing complexity and saving significant cost.”

“This project is about completely transforming on-train connectivity for the digitalization strategy of the railway sector. It’s about providing massive high-quality wireless capacity to trains to enable cloud-based applications that improve performance and security in the railway sector. It’s also about being able to support new business and passenger applications,” said Manuel Alfageme, head of smart systems innovation, COMSA Industrial. “At COMSA, we have a formidable record of leading the way with rail innovation. By jointly demonstrating the technical and commercial viability of this technology in a live operational environment, we’re showing train operators and railway infrastructure managers that open, scalable and agile 5G networks are now possible in the railway vertical. The time has come for a new generation of integrated railway infrastructure.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye